<DOC>
	<DOCNO>NCT01839344</DOCNO>
	<brief_summary>The purpose study measure effect quercetin glucose tolerance postprandial endothelial function comparison placebo Acarbose participant Type 2 Diabetes . Primary Hypothesis : We hypothesize administration quercetin ( 2g oral ) prior 100g maltose tolerance test ( MTT ) result decrease postprandial blood glucose 60 minute compare placebo . Acarbose ( 100mg oral ) , pharmaceutical alpha-glucosidase inhibitor , serve positive control . Secondary Hypothesis : We hypothesize administration quercetin ( 2g oral ) reduce Area Under Glucose Curve ( AUC ) 2 hour follow 100g MTT compare placebo . AUC hypothesize comparable quercetin Acarbose . Tertiary hypothesis : We hypothesize administration quercetin ( 2g oral ) prior 100g MTT result small reduction flow mediate dilation ( FMD ) measure increase Reactive Hyperemia Index ( RHI ) 90 minute compare placebo .</brief_summary>
	<brief_title>Effects Quercetin Blood Sugar Blood Vessel Function Type 2 Diabetes .</brief_title>
	<detailed_description>This phase II , crossover , double-blinded , control trial 20 participant type 2 diabetes design measure effect quercetin glucose tolerance postprandial endothelial function comparison placebo Acarbose . Glucose tolerance insulin excursion measure 0 , 30 , 60 , 120 minute follow 100g maltose tolerance test ( MTT ) . Each participant blindly rotate three single individual dos placebo , quercetin ( 2g oral ) , Acarbose ( 100mg oral ) prior MTT 3 separate occasion . Each participant serve control comparison intervention . Fasting post-MTT endothelial function measure peripheral tonometry ( Itamar EndoPAT ( Peripheral Arterial Tone ) 2000 ) report reactive hyperemia index ( RHI ) . EndoPAT test perform prior fast blood collection 90 minute follow MTT , clinical research visit . Exploratory data also collect post-MTT increase gamma-glutamyltransferase ( GGT ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<mesh_term>Quercetin</mesh_term>
	<criteria>Adults age 1875 year International Classification diseases book 9 ( ICD9 ) diagnosis type 2 diabetes ( 250.XX ) . As lack clarity ICD9 cod provider notorious type 2 diabetes , specify ICD9 diagnosis 250.XX order capture subtypes type 2 diabetes ( see ICD9 book information subtypes ) . Patients stable dose ( consistent dose one month ) medication supplement . Hemoglobin A1c ( HbA1c ) 6.510.5 % within last year . Since quercetin 's effect blood sugar endothelial function may relate antioxidant property , interested look effect patient high level oxidative damage associate high blood sugar ( i.e . elevate HbA1c &gt; 6.5 % ) , yet exclude severe hyperglycemia . Stable exercise diet last 1 month . Labs ( HbA1c , aspartate aminotransferase ( AST ) , Alanine transaminase ( ALT ) , Glomerular filtration rate ( GFR ) , creatinine ) measure within last year meet inclusion/exclusion criterion run . Current use insulin Acarbose ( due possible hypoglycemia ) ; insulin exclusion ensure exclusion type 1 diabetes . Current use quercetin . History myocardial infarction within last 6 month , angina , ischemic stroke , uncontrolled hypertension systolic great 180 diastolic great 110 . Clinical objective find suggestive congestive heart failure Class III IV shortness breath Activities Daily Living ( ADLs ) . Recent ( &lt; 14 day ) history infection . During telephone screening , patient acute infection last 14 day ask may recontact 34 week second telephone screen determine qualification ( include resolution recent infection &gt; 14 day ) . Stage IV high kidney disease ( eGFR &lt; 30 ) . Liver disease ( define AST ALT &gt; 2 x high normal ( accord lab range ) ) . Prior diagnosis genetic abnormality carbohydrate metabolism ( e.g . Congenital SucraseIsomaltase , Pompe Disease ) . Pregnant breast feeding . Mental illness cognitive impairment prohibit candidate making informed choice ( determine discretion PI consult Research Assistants/Study Coordinator need ) assess throughout telephone screening informed consent process . Hypersensitivity quercetin Acarbose ; base past allergic symptom take either drug drug supplement . Diagnosis celiac disease/ '' sprue '' . Contraindications EndoPAT : Participants antiplatelet medication exclude visible bruising ( beyond petechia ) . Participants exclude unwilling fast 12 hour prior maltose tolerance test and/or EndoPAT . Participants exclude take nitroglycerine , Cialis , Viagra 12 hrs test day . In order accommodate finger probe , participant exclude unwilling clip fingernail index finger short prior test day . Index finger nail must extend past finger test day . Bilateral upper extremity lymphedema . Contraindications Acarbose : Current diabetic ketoacidosis . Inflammatory bowel disease ; colonic ulceration ; partial intestinal obstruction , patient predispose intestinal obstruction ; chronic intestinal disease mark maldigestion malabsorption ; hernia . Cirrhosis Renal impairment ( serum creatinine &gt; 2 mg/dL ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>hyperglycemia</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>endothelial dysfunction</keyword>
	<keyword>quercetin</keyword>
	<keyword>Acarbose</keyword>
	<keyword>glucose tolerance</keyword>
	<keyword>maltose</keyword>
</DOC>